Cell culture compositions with antioxidants and methods for polypeptide production

What is this patent about?

’710 is related to the field of cell culture manufacturing and biotechnology, specifically addressing the optimization of media for the production of recombinant polypeptides. In commercial protein production, such as for monoclonal antibodies, achieving high titers often leads to undesirable quality attributes, including increased color intensity in the final product. This is particularly problematic for high-concentration liquid formulations (e.g., ≥100 mg/mL) required for subcutaneous delivery, where oxidative degradation pathways involving reactive oxygen species can negatively impact the visual profile and regulatory compliance of the therapeutic protein.

The underlying idea behind ’710 is that the addition of specific antioxidant compounds to the cell culture medium can suppress the formation of color-causing variants without compromising cell viability or protein yield. The inventor discovered that certain molecules, particularly those in the hypotaurine family, act as effective stabilizers during the growth and production phases. By incorporating these components into either basal or feed media, the chemical environment is modified to prevent the oxidation of sensitive amino acid residues like tryptophan and tyrosine, which are often the culprits behind the browning or yellowing of concentrated protein solutions.

The claims of ’710 focus on a method for producing recombinant polypeptides with reduced color intensity by culturing Chinese hamster ovary (CHO) cells in a medium supplemented with at least one of eight specific components. These components include hypotaurine, s-carboxymethylcysteine, carnosine, anserine, butylated hydroxyanisole, lipoic acid, quercitrin hydrate, and taurine. The independent claims specifically protect the use of these additives to achieve a measurable reduction in color intensity compared to standard media, ensuring the resulting composition meets stringent pharmaceutical appearance standards.

In practice, the invention is implemented by adding the selected antioxidant, such as hypotaurine, as a bolus dose at the start of the culture cycle (Day 0) or incrementally through feed media. The process maintains standard parameters for pH, temperature, and dissolved oxygen while the CHO cells secrete the target antibody into the nutrient-rich broth. Following the production phase, the polypeptide is recovered and purified through techniques like Protein A affinity chromatography. The effectiveness of the invention is validated by concentrating the purified protein to high levels and utilizing quantitative color assays to confirm a reduction in intensity, often ranging from 5% to 50%.

This approach differs from prior solutions by targeting the cell culture stage rather than attempting to remove color during downstream purification or through formulation adjustments. While traditional methods focus on titer optimization, ’710 identifies that the oxidative environment of the bioreactor itself is a primary driver of color issues. By utilizing chemically defined constituents like hypotaurine, the invention provides a predictable and cost-effective way to maintain product quality attributes—specifically color and charge heterogeneity—without the need for complex post-translational modifications or specialized purification resins to strip out colored impurities.